Our Predesigned siRNA Library solutions help biotechnology teams, pharmaceutical research groups, CROs, academic laboratories, and screening facilities move from a gene list to an arrayed RNA interference workflow with less design and procurement burden. The libraries are built for systematic loss-of-function studies in which each well contains a defined siRNA reagent targeting a known gene, enabling direct linkage between gene knockdown and an observed molecular, cellular, or phenotypic response.
We support genome-wide, druggable-genome, gene-family, pathway-focused, and cherry-pick siRNA library projects with flexible pooled or individual duplex formats, 96-well or 384-well plate configurations, screening controls, and follow-up reagents. Projects can also be connected with our RNA interference services, siRNA screening services, and downstream knockdown analysis to create a coordinated research workflow from library selection through hit confirmation.
Gene Coverage and Annotation: A library is only useful when its target list matches the biological question and current transcript annotations. We review species, gene identifiers, transcript coverage, duplicate entries, retired symbols, and pathway membership so that procurement teams receive a coherent, traceable collection rather than a plate set with unresolved mapping gaps.
Potency Versus Off-Target Risk: High-throughput RNAi projects must balance efficient knockdown with the risk of seed-mediated and sequence-dependent off-target effects. Predesigned candidates are selected using sequence, thermodynamic, homology, repeat, and transcript-context criteria, while follow-up planning considers independent duplex confirmation rather than relying on a single screening reagent.
Pooled or Individual Formats: A pooled reagent can simplify primary screening and reduce well count, but individual duplexes provide more direct sequence-level interpretation and are valuable for deconvolution. We help customers choose the format according to screen size, assay capacity, expected hit rate, and the level of confirmation required after the primary screen.
Plate and Automation Compatibility: Library handling failures often begin with plate density, dead volume, well position, resuspension, or liquid-handling incompatibility. We align plate type, fill pattern, quantity per well, control-well allocation, and plate-map structure with the intended manual or automated workflow before synthesis and dispensing are finalized.
Control and Hit-Validation Planning: Positive controls, non-targeting controls, mock-transfection wells, and assay-specific reference conditions are necessary for interpreting plate quality and setting hit thresholds. We can pair library supply with siRNA control products, RNAi transfection optimization, and hit follow-up reagents so that primary-screen signals can be tested with a defined confirmation strategy.
Our service model is designed for organizations that need more than a generic catalog plate. We help define the most appropriate target collection, reagent architecture, plate configuration, control strategy, and follow-up plan for functional genomics and high-throughput RNAi screening.
Library content can be selected from broad predesigned collections or assembled as a focused cherry-pick set. Sequence design, synthesis, normalization, dispensing, plate mapping, and resupply planning can be coordinated with our siRNA design services and siRNA synthesis services.
| Catalog | Product Name | Inquiry |
| BRJ-001 | Human Apoptosis siRNA Library | Inquiry |
| BRJ-002 | Human Cancer Genome siRNA Library | Inquiry |
| BRJ-003 | Human Cell Cycle Regulation siRNA Library | Inquiry |
| BRJ-004 | Human Cell Surface siRNA Library | Inquiry |
| BRJ-005 | Human DNA Damage Response siRNA Library | Inquiry |
| BRJ-006 | Human Drug Targets siRNA Library (384well) | Inquiry |
| BRJ-007 | Human Drug Targets siRNA Library (96well) | Inquiry |
| BRJ-008 | Human Drug Transporter siRNA Library | Inquiry |
| BRJ-009 | Human Druggable Genome siRNA Library (384well) | Inquiry |
| BRJ-010 | Human Druggable Genome siRNA Library (96well) | Inquiry |
| BRJ-011 | Human Epigenetics siRNA Library | Inquiry |
| BRJ-012 | Human Genome siRNA Library | Inquiry |
| BRJ-013 | Human GPCR siRNA Library | Inquiry |
| BRJ-014 | Human Ion Channel siRNA Library | Inquiry |
| BRJ-015 | Human Kinase siRNA Library | Inquiry |
| BRJ-016 | Human Membrane Trafficking siRNA Library | Inquiry |
| BRJ-017 | Human Nuclear Hormone Receptor siRNA Library | Inquiry |
| BRJ-018 | Human Phosphatase siRNA Library | Inquiry |
| BRJ-019 | Human Protease siRNA Library | Inquiry |
| BRJ-020 | Human Transcription Factor siRNA Library | Inquiry |
| BRJ-021 | Human Tumor Suppressor siRNA Library | Inquiry |
| BRJ-022 | Human Ubiquitin siRNA Library | Inquiry |
The most appropriate library depends on how broadly the project must search, how many wells the assay can support, and how much sequence-level resolution is needed during primary screening. The comparison below helps research and procurement teams align library scope with experimental intent.
| Library Type | Best-Fit Research Need | Typical Target Scope | Recommended Reagent Format | Key Selection Consideration |
| Whole-Genome Library | Broad, hypothesis-light discovery when the responsible genes are not yet defined | Large protein-coding gene collection for a supported species | Arrayed pooled siRNA for primary screening; individual duplexes for follow-up | Requires sufficient automation, storage, assay robustness, and data-analysis capacity |
| Druggable Genome Library | Target discovery within gene classes commonly prioritized by research programs | Curated set of enzymes, receptors, transporters, signaling proteins, and other actionable target classes | Pooled or individual arrayed format | Confirm that the included gene definition matches the project's internal target taxonomy |
| Gene Family Library | Systematic comparison of related genes with shared molecular functions | Kinases, phosphatases, GPCRs, ion channels, proteases, transcription factors, or other families | Pooled format for speed; individual format for direct sequence concordance | Review family membership, paralogs, and overlapping annotations before plate finalization |
| Pathway Library | Mapping regulators, effectors, and modifiers within a defined biological process | Focused pathway core plus optional upstream, downstream, and cross-talk genes | Pooled or individual arrayed format with pathway-specific controls | Gene-list quality is often more important than library size |
| Cherry-Pick Library | Testing a customer-selected list derived from omics, literature, prior screens, or internal models | Flexible list from a small pilot set to a large targeted panel | Customer-defined pooled, individual, or mixed configuration | Identifier reconciliation and custom plate design should be completed before synthesis |
| Hit-Validation Library | Confirming and prioritizing primary-screen hits | Shortlisted genes with independent duplexes, controls, and replicate positions | Individual siRNAs, concentration series, or orthogonal sequence sets | Confirmation should separate on-target evidence from transfection, toxicity, and seed-driven effects |
A predesigned siRNA screening library must be configured around the practical conditions of the assay. This matrix summarizes the main technical decisions that affect interpretability, handling, and follow-up efficiency before a library enters production.
| Planning Parameter | Available Direction | Why It Matters | Customer Input Needed | Resulting Deliverable |
| Reagent Architecture | Pooled siRNAs, individual duplexes, or a staged combination | Determines well count, primary-screen efficiency, and deconvolution burden | Screen size, assay throughput, and confirmation strategy | Gene-level reagent map with pool composition or duplex identifiers |
| Plate Density | 96-well or 384-well configuration | Affects automation compatibility, cell number, reagent consumption, and edge effects | Instrument format, liquid-handler compatibility, and assay volume | Plate layout matched to the intended screening platform |
| Reagent Presentation | Dried-down wells or normalized solution | Influences storage, resuspension, dispensing, and freeze-thaw exposure | Laboratory handling workflow and preferred stock concentration | Defined presentation format with handling instructions |
| Control Strategy | Positive, non-targeting, mock, untreated, and assay-specific controls | Supports transfection assessment, plate normalization, and hit-threshold definition | Cell model, phenotype, readout, and known responsive genes | Control panel and plate-position plan |
| Annotation Review | Gene symbol, accession, transcript, isoform, and species alignment | Reduces mismatched targets and makes downstream data integration more reliable | Preferred reference build, gene list, and inclusion rules | Curated target list with exception flags |
| Transfection Readiness | Standard transfection workflow or alternative delivery-compatible planning | Cell-type-dependent delivery variability can obscure true gene-knockdown phenotypes | Cell type, plate format, reagent history, and toxicity limits | Pilot recommendations linked to transfection optimization |
| Readout Alignment | Reporter, viability, morphology, imaging, transcript, protein, or multiplex assay | Timing and assay sensitivity influence both hit detection and interpretation | Endpoint, detection method, and expected response window | Screen-ready format with assay-aware control and timing guidance |
| Hit Follow-Up | Deconvolution, independent duplexes, dose response, and orthogonal readouts | Primary hits require confirmation before they support gene-level conclusions | Expected hit rate, available follow-up capacity, and validation endpoint | Secondary library or custom confirmation set with traceable linkage to primary hits |
Our workflow connects biological scope, sequence selection, plate engineering, quality review, and downstream screening support. Each stage is designed to reduce avoidable changes after production has started and to give research teams a clear record of what is present in every well.
We confirm the species, biological question, target breadth, cell model, assay endpoint, screening scale, and expected follow-up strategy. This establishes whether the project requires a whole-genome collection, a predefined sublibrary, or a focused cherry-pick panel.
The proposed target list is checked for gene-symbol consistency, duplicate entries, retired identifiers, species mismatches, transcript relevance, and unsupported targets. Exceptions are returned for customer review before the final library scope is locked.
We align pooled versus individual siRNA architecture, number of designs per gene, quantity per well, presentation format, and optional chemical modifications with the assay and hit-validation plan. This step prevents a primary-screen format from becoming a bottleneck during confirmation.
Plate density, target ordering, control locations, empty wells, replicates, edge positions, identifiers, and daughter-plate requirements are defined. A draft map is reviewed before synthesis and dispensing so that the delivered plates match the screening facility's workflow.
siRNA reagents are synthesized, processed, normalized, pooled where applicable, and dispensed according to the confirmed configuration. Identity, quantity, plate-map integrity, and agreed quality attributes are reviewed before release.
The library is delivered with plate maps, target annotations, reagent information, and handling guidance. Post-delivery support can include pilot-screen planning, resupply, deconvolution sets, mRNA-level detection, and protein-level detection for selected hits.
A screening library must perform as a coordinated system of sequences, plates, controls, maps, and follow-up reagents. Our platform focuses on the decisions that determine whether a library can be implemented cleanly in a real screening environment and interpreted with confidence.
Predesigned siRNA libraries support arrayed loss-of-function studies in which researchers need a scalable way to connect gene suppression with a measurable response. Library scope and format can be adjusted to the biological question, assay complexity, and level of validation required.
Whether your project requires a genome-wide siRNA library, a druggable-genome panel, a pathway-focused set, or a custom cherry-pick collection, our team can help define the target scope, reagent format, plate layout, control strategy, and hit-follow-up plan. We support research groups that need a practical bridge between gene-list selection and screen-ready arrayed reagents, with optional integration into transfection optimization, RNAi screening, and knockdown analysis. Contact us to discuss your species, gene list, plate format, assay readout, and preferred pooled or individual siRNA configuration.
We offer comprehensive libraries targeting specific pathways including apoptosis, kinase, epigenetics, and whole-genome collections, with each gene targeted by multiple optimized siRNA sequences.
Our proprietary algorithm evaluates base composition, thermodynamic properties, and off-target potential through BLAST analysis, while chemical modifications further enhance specificity and stability.
Libraries are provided in multi-well plates with individual gene targeting, available in both pre-mixed formats and single-siRNA configurations for flexible experimental setups.
Extensive testing demonstrates >75% knockdown efficiency for 80% of siRNAs, with over 40% achieving >90% target silencing, validated through real-time PCR analysis.
Yes, we provide fully customizable library services, allowing researchers to target specific gene combinations or create hybrid libraries tailored to unique experimental requirements.
Our collections primarily focus on human genomes, with additional options available for other model organisms to support comparative genomic studies.
Loading ......
